Vetoquinol SA (ENXTPA: VETO)
Health Care · Pharmaceuticals · FR
€70.50
0.00% today · -6.3% 1Y
Vetoquinol SA (ENXTPA: VETO) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $956.52M and employs 2,454 people.
Over the last twelve months the share price has lost 6.3%, trading between 67.20 and 91.50.
Tweenvest scores Vetoquinol SA across four factors: quality 86/100, value 84/100, growth 27/100, dividend 73/100. Its strongest factor is quality.
VETO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $956.52M
- Revenue (TTM)
- $617.22M
- P/E
- 14.28
- EPS
- 4.94
- Dividend yield
- 1.31%
- Beta (5Y)
- 0.88
- 52-week high
- €91.50
- 52-week low
- €67.20
- Avg volume (3M)
- —
- Shares outstanding
- 11.62M
- Employees
- 2,454
- Next earnings
- —
About Vetoquinol SA
Vetoquinol S.A. is a prominent veterinary pharmaceutical enterprise dedicated to the innovation, development, and global commercialization of both medicinal and non-medicinal solutions for animal health. Its operations extend across Europe, the Americas, and the Asia Pacific regions. The company's diverse product portfolio addresses crucial therapeutic areas, including mobility, pain management, and inflammation; dermatological care and hygiene; anti-parasitic treatments; udder health; infectious disease control; reproductive solutions; behavior modification; internal medicine; and cardiovascular-renal support. These offerings cater to a wide spectrum of animals, encompassing livestock such as cattle, sheep, pigs, and poultry, alongside companion animals like dogs. Founded in 1933, Vetoquinol S.A. is headquartered in Lure, France, and functions as a subsidiary of Soparfin SCA.
- ISIN
- FR0004186856
- Founded
- 1933
- Listed since
- Nov 17, 2006
- Exchange
- Euronext Paris
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,249.71 | -0.45% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $272.79 | +0.94% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.65 | -1.25% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.03 | -0.16% |
Figures last refreshed Aug 18, 2026.